Virax Biolabs Group Ltd - Ordinary Shares - Class A
VRAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$410.58K
Close$
$1.23
48.6% downside
Current Fair Value
48.6% downsideOvervalued by 48.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $410,575.00 |
|---|---|
| Enterprise Value | $-5,613,947.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.64 |
| Beta | 1.36 |
| Outstanding Shares | 397,590 |
Return
| Return on Equity | -146.29% |
|---|---|
| Return on Assets | -133.16% |
| Return on Invested Capital | -164.44% |
Valuation & Multiples
| P/E Ratio | -0.09 |
|---|---|
| PEG | 0.47 |
| Price to Sales | - |
| Price to Book Ratio | 0.13 |
| Enterprise Value to Revenue | -299.35 |
| Enterprise Value to EBIT | 0.45 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.07 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 1, 2026
EPS Estimate
$-1.50
Average shareholder expectationRevenue Estimate
$13,893
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-1.75
Average shareholder expectationRevenue Estimate
$12,423
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.25%▲ 9.02% |
|---|---|
| Total Invested | $202,209▲ 1573.22% |
| Investors Holding | 3▼ 2.00% |
ESG Score
No data